← Back to Home

Enhancing Ammonia Clearance Through RNA Editing: Korro’s Hyperammonemia Drug Enters Human Trials

KRRO-121 aims to use RNA editing to enhance the body’s ability to clear ammonia. The first cohort of healthy volunteers has been dosed, but whether it can help patients with urea cycle disorders control blood ammonia levels remains a question for subsequent trials.

By SURL BioNews

For patients with urea cycle disorders, failure to adequately clear ammonia from the blood can cause severe neurological damage and even become life-threatening. An RNA-editing therapy designed to enhance ammonia clearance has now entered human trials: Korro Bio announced on October 5 that the first cohort of healthy volunteers had been dosed with its drug candidate KRRO-121 in the Phase 1/2 ANCHOR trial.

The study, currently underway in Australia, will first assess the drug’s safety, tolerability, and pharmacokinetics in humans. According to the company’s announcement and the same press release filed with the U.S. Securities and Exchange Commission (SEC), participants in the first cohort received a single dose of 2 milligrams per kilogram of body weight. This announcement reports dosing progress; it does not yet provide results on human safety or ammonia-lowering effects.

KRRO-121 is a GalNAc-conjugated RNA-editing oligonucleotide. According to Korro, it is designed to alter the target RNA so that cells produce a more stable, novel form of glutamine synthetase (GS), thereby enhancing ammonia clearance. This strategy focuses on strengthening metabolic capacity rather than individually correcting the different gene mutations that cause urea cycle disorders, so the company hopes it could eventually be applicable to patients with multiple genotypes.

To test this concept, the trial begins with gradual dose escalation. The single ascending dose portion is expected to enroll up to 30 healthy volunteers across up to five cohorts; the subsequent multiple ascending dose portion is planned to enroll up to 20 people across two cohorts. Both portions are placebo-controlled, and the trial registration number listed in the announcement is NCT07773246.

The subsequent patient study will move the assessment to clinical activity. The company plans to enroll up to 15 patients with urea cycle disorders of different genotypes for multiple dosing, assessing the drug’s effects in addition to safety and pharmacokinetics. Patient dosing is expected to begin in the first half of 2027, with interim data released in the second half. These remain planned timelines, and the patient phase also requires regulatory approval.

In terms of its mechanism, RNA editing alters the instructions cells use to make proteins rather than DNA itself. Korro hopes this temporary editing will offer room for adjustment, but actual data are needed to establish how long the effects last, whether repeated dosing is safe, and whether preclinical observations can be reproduced in humans. The company also lists hepatic encephalopathy as a potential development direction for KRRO-121, while the patient trial plans announced this time focus on urea cycle disorders.

Dosing this first cohort brings the concept of enhancing ammonia clearance into human testing. An evidence gap remains before it can be shown to reduce the risk of hyperammonemic crises and lessen the burden of existing treatment. Even if the subsequent small patient study shows signs of improvement in blood ammonia levels, more comprehensive follow-up will still be needed to determine whether the benefits are durable and sufficient to change patients’ daily lives.

References

  1. Korro Bio / GlobeNewswire
  2. Korro Bio / U.S. Securities and Exchange Commission